Abbott Laboratories (NY:ABT)

97.50 +0.81 (+0.84%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9

...

58 59 Next >

Insulet (PODD) Shakes the Market with Q4 Earnings Beat as Omnipod 5 Dominance Continues

February 18, 2026

Insulet Corporation (NASDAQ:PODD) delivered a commanding performance in its fourth-quarter earnings report released today, February 18, 2026. The medical device leader announced an adjusted earnings...

Via MarketMinute

Topics Earnings

Medtronic (MDT): The Sleeping Giant Awakes with Strong Q3 FY26 Momentum

February 17, 2026

Today’s Date: February 17, 2026 Introduction Medtronic plc (NYSE: MDT) has long been the sleeping giant of the medical technology sector. For years, the Dublin-domiciled powerhouse was viewed by Wall...

Via Finterra

Topics Artificial Intelligence Earnings Economy

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

January 23, 2026

Via Chartmill

Greenland Truces and Intel’s Earnings Bruises: Wall Street’s Identity Crisis ↗

January 23, 2026

Via Chartmill

Which S&P500 stocks have an unusual volume on Thursday? ↗

January 22, 2026

Via Chartmill

2 of Wall Street’s Favorite Stocks with Competitive Advantages and 1 We Turn Down

February 15, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky

February 12, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever ↗

February 12, 2026

Abbott is the name behind many well-known products.

Via The Motley Fool

1 Reason I'm Never Selling AbbVie Stock ↗

February 12, 2026

This Dividend King has staying power.

Via The Motley Fool

Topics Intellectual Property

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Northfield Bancorp Inc. (Nasdaq - NFBK), Coterra Energy Inc. (NYSE - CTRA), Exact Sciences Corporation (Nasdaq – EXAS), Semrush Holdings, Inc. (NYSE – SEMR)

February 09, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Pure-Play Pivot: Decoding Becton Dickinson’s (BDX) Q1 Results and the $17.5B Waters Combination

February 09, 2026

Today, February 9, 2026, marks a watershed moment for Becton, Dickinson and Company (NYSE: BDX). The medical technology giant, commonly known as BD, has officially closed its transformative $17.5...

Via Finterra

Topics Artificial Intelligence Economy Product Recall

The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map

February 06, 2026

As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A...

Via MarketMinute

Topics Artificial Intelligence Economy

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal ↗

February 05, 2026

Via MarketBeat

Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)

February 05, 2026

February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left...

Via Finterra

Topics Product Recall World Trade

2 Healthcare Dividend Stocks That are Just What the Doctor Ordered ↗

February 03, 2026

AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.

Via The Motley Fool

Topics Intellectual Property

February 03, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

The Best Dividend King to Buy With $150 ↗

February 02, 2026

The stock is near its 52-week low.

Via The Motley Fool

Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race

February 02, 2026

In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The...

Via MarketMinute

Topics Artificial Intelligence

Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist ↗

January 31, 2026

These market giants make great long-term investments.

Via The Motley Fool

5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call

January 29, 2026

Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing challenges in its nutrition segment. Management attributed this...

Via StockStory

Topics Earnings

3 Reasons to Buy This Dividend King After Its Steep Sell-Off ↗

January 26, 2026

Investors' reaction to this Dividend King's Q4 revenue miss was overdone.

Via The Motley Fool

Topics Earnings

The Best Dividend Stocks to Buy and Hold Forever ↗

January 26, 2026

These stocks offer highly attractive dividends and staying power.

Via The Motley Fool

Topics Intellectual Property

Is Abbott’s January Pullback a Good Time to Buy? ↗

January 24, 2026

Via MarketBeat

Which stocks are moving after the closing bell on Friday? ↗

January 23, 2026

Via Chartmill

Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles

January 23, 2026

Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare

January 23, 2026

The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence...

Via MarketMinute

Topics Artificial Intelligence Economy

ABT Q4 Deep Dive: Nutrition Weakness and Innovation Shape 2026 Outlook

January 23, 2026

Healthcare product and device company Abbott Laboratories (NYSE:ABT) missed Wall Street’s revenue expectations in Q4 CY2025 as sales rose 4.4% year on year to $11.46 billion. Its non-GAAP profit of...

Via StockStory

Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting...

Via MarketMinute

Topics Economy

These S&P500 stocks are moving in today's session ↗

January 22, 2026

Via Chartmill

Why Abbott Laboratories (ABT) Shares Are Sliding Today

January 22, 2026

Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.